Does Ozempic Help Arthritis? What a Rheumatologist Wants You to Know

Every week in my clinic, patients ask me some version of the same question: “I’ve heard Ozempic helps with weight — but could it actually help my arthritis?” It’s a fair question, and the honest answer is that the science has shifted dramatically over the past three years. GLP-1 medications, originally built for diabetes and weight loss, are turning out to do something we didn’t expect: they calm inflammation throughout the body. For people living with rheumatoid arthritis, psoriatic arthritis, osteoarthritis, lupus, and gout, that has real implications.

Let me walk you through what the research actually shows, what I see in practice, and — just as importantly — where the limits and cautions are.

What Are GLP-1 Medications, and Why Would a Rheumatologist Care?

Ozempic, Wegovy, Mounjaro, and Zepbound are the brand names patients hear most often, and the confusion among them is constant. Here’s the simple version.

There are two molecules in this family. The first is semaglutide: Ozempic is the lower-dose version approved for type 2 diabetes, and Wegovy is the higher-dose version approved for obesity. Same molecule, different doses. The second is tirzepatide: Mounjaro is approved for diabetes and Zepbound for weight management — again, same molecule, two names. The clinically meaningful difference between the two is that semaglutide activates one receptor (GLP-1), whereas tirzepatide activates two (GLP-1 and GIP), which tends to make it more effective for weight loss.

So why does a rheumatologist care about diabetes and weight-loss drugs?

Because fat tissue is not silent. It pumps out inflammatory molecules — IL-6, TNF-alpha, and IL-1 — the very same molecules that drive rheumatoid arthritis, psoriatic arthritis, lupus, and even osteoarthritis.

They are also the molecules that expensive biologic drugs are designed to block. When you reduce fat-driven inflammation, your existing arthritis medications often start working better.

How Does Ozempic Reduce Inflammation — Even Without Weight Loss?

This is the part that surprises people. GLP-1 medications appear to reduce inflammation through several mechanisms, and not all of them require weight loss.

The first is the obvious one: reducing fat-driven inflammation. Losing even 5 to 10 percent of body weight quiets the inflammatory output of fat tissue. But the others are more interesting. GLP-1 medications appear to have a direct anti-inflammatory action, dampening the NF-kB pathway — one of the body’s master switches for inflammation — independent of weight change. They improve the diversity of the gut microbiome, which matters because there is a genuine gut-joint connection in autoimmune disease. They reverse insulin resistance, which many arthritis patients have without knowing it and which feeds the inflammation cycle. And they reduce oxidative stress, which helps protect cartilage and joint tissue.

The practical upshot is that the anti-inflammatory effect seems to operate even at low doses — what clinicians increasingly call microdosing, which I’ll return to below.

Can Ozempic Help Rheumatoid Arthritis?

Rheumatoid arthritis is the most common autoimmune disease I treat. Most patients do well on methotrexate, biologics, and JAK inhibitors. But for some, the inflammation never fully settles — in part because their fat tissue is producing inflammatory molecules around the clock, undercutting the effect of the biologic.

The most direct evidence so far comes from a 2025 study out of UCLA, published in ACR Open Rheumatology. Researchers followed 173 patients with rheumatoid arthritis and a BMI of at least 27 who took semaglutide or tirzepatide, compared with 42 who were prescribed the medication but never started it. After up to a year, the GLP-1 group showed significantly lower disease activity, less pain, improved cholesterol and HbA1c, and meaningful weight loss, with inflammatory markers (CRP and ESR) also improving. It’s worth being clear-eyed about the study’s limits: it was a single-center, retrospective chart review, not a randomized trial, and nearly a third of patients discontinued the medication, most often due to gastrointestinal side effects.

The key takeaway I give my own patients: GLP-1 medications do not replace methotrexate or a biologic. They appear to make them work better.

Can Ozempic Help Psoriatic Arthritis?

Let me tell you about a patient — I’ll call him Daniel. He was 33, weighed 280 pounds, and had battled psoriasis and psoriatic arthritis for a decade. Multiple medications had failed him, and even a weight-based biologic infusion wasn’t giving him adequate control. About three years ago, I started him on a GLP-1 medication. Within months his skin began to clear, his joint pain eased, and his morning stiffness improved. By six months, his disease was better controlled than it had been in years.

The research is starting to catch up to stories like Daniel’s. At the 2025 ACR Convergence meeting, a study of psoriatic arthritis patients on GLP-1 therapy reported improvements in joint pain, lower disease activity, and lower CRP. Even more striking was a separate large analysis, also presented at ACR Convergence 2025 by researchers at Jefferson Health-Einstein in Philadelphia, which used a nationwide database of more than 4,000 psoriatic arthritis patients on GLP-1 medications compared with over 86,000 who weren’t. The GLP-1 group had notably lower rates of death and major cardiac events. Since patients with psoriatic arthritis already carry an elevated cardiovascular risk, this isn’t only about joint pain — it may also be about protecting the heart.

Does Ozempic Help Osteoarthritis and Knee Pain?

Osteoarthritis is often dismissed as simple “wear and tear,” but we now understand that low-grade inflammation drives it too — it isn’t purely mechanical. That reframing is why the STEP-9 trial, published in the New England Journal of Medicine in late 2024, changed how I think about knee osteoarthritis.

STEP-9 enrolled 407 adults with obesity and moderate knee osteoarthritis across 11 countries, randomly assigning them to semaglutide or placebo alongside lifestyle changes. After 68 weeks, the semaglutide group lost about 13.7 percent of body weight, compared with 3.2 percent on placebo. More importantly for arthritis, their knee pain dropped 41.7 points on the WOMAC scale versus 27.5 on placebo, with significantly better physical function — a pain reduction larger than weight loss alone would explain. Semaglutide is not approved for osteoarthritis, but findings like these are prompting rheumatologists and orthopedic surgeons to rethink how we manage knee disease before resorting to joint replacement.

Will Ozempic Cause a Gout Flare?

This one is genuinely nuanced, and I won’t pretend otherwise. When you lose weight rapidly on a GLP-1 medication, the breakdown of fat releases purines into the bloodstream, which convert to uric acid. In some patients, this temporarily raises uric acid and can trigger a gout flare in the first few months. I’ve seen it in my own practice, and the research confirms it’s real. The same thing happens after bariatric surgery or any rapid weight loss.

But it’s a short-term effect. Over the longer term, once weight stabilizes, GLP-1 medications appear to lower uric acid and reduce flare frequency, leaving patients better off. The important point is that managing this transition takes a clinician who understands both gout and weight-loss therapy — someone who can protect you through that early window, often with low-dose colchicine or by adjusting your urate-lowering therapy. This is not a job for a weight-loss clinic alone.

Can Ozempic Help Lupus and Other Autoimmune Diseases?

Here the evidence is earlier, but it’s growing quickly. Lupus is driven by inflammation, and while our standard treatments calm the immune attack, many lupus patients also struggle with steroid-related weight gain, insulin resistance, and elevated cardiovascular risk. Small studies in lupus patients on GLP-1 therapy have suggested fewer flares and possible protection against progression to kidney disease in lupus nephritis. A broad analysis presented at ACR Convergence 2025 even associated GLP-1 use with a reduced risk of developing new autoimmune diseases overall.

For Sjögren’s syndrome and ankylosing spondylitis, we don’t yet have specific large trials — but the same underlying biology applies: calm the metabolic inflammation, and the autoimmune attack often calms with it. I want to be honest that these are not approved treatments for lupus or Sjögren’s. For carefully selected patients, though, they may be a powerful addition to standard therapy.

What Is GLP-1 Microdosing for Arthritis?

This is one of the most interesting — and underused — developments in rheumatology. When most people picture Ozempic or Zepbound, they imagine large doses and dramatic weight loss. But what I see in clinic is that even very small doses, what clinicians call microdoses, can produce meaningful improvements in arthritis patients. That makes sense given that the anti-inflammatory effects work through pathways independent of weight loss — you don’t need to lose 15 percent of your body weight to get the benefit.

I think of a patient from Arizona who was already maxed out on a DMARD and a biologic together, yet still having multiple flares a month, exhausted and in pain. Four months after starting a GLP-1 microdose, her flares dropped to about one a month and her energy improved markedly. We are now tapering her medication down rather than escalating it. This approach is especially relevant for patients who aren’t significantly overweight but carry metabolic inflammation.

Why Is Ozempic So Hard to Get Prescribed?

If the science is this encouraging, why is it such a fight to get a prescription? Patients ask me this constantly, and the honest answer is economics. More than 80 percent of U.S. insurance plans put up barriers — high out-of-pocket costs, strict coverage rules, and requirements to fail multiple diets first. The reason is budgetary: U.S. spending on GLP-1 medications rose from roughly $13 billion in 2018 to nearly $72 billion in 2023, and insurers are responding to that pressure, not to patient need. So even though research increasingly supports GLP-1 use in arthritis, autoimmune disease, fatty liver, kidney disease, and heart health, coverage outside of diabetes remains a constant battle.

The encouraging part is that new trials are unlocking more uses every year, and some clinics — including ours — are already helping patients with chronic pain and autoimmune disease access these medications, including in microdoses, even when they don’t fit the traditional weight-loss criteria.

Who Should Be Cautious With GLP-1 Medications?

These drugs aren’t right for everyone. They are generally avoided in people with a personal or family history of medullary thyroid cancer or MEN2 syndrome, a history of pancreatitis, severe gastroparesis, or during pregnancy and breastfeeding, and they require caution in significant kidney or liver disease. The most common side effects are gastrointestinal — nausea, diarrhea, constipation — which often improve over time. As with any chronic-disease therapy, the decision should be individualized with a clinician who knows your full history.

The Bottom Line

GLP-1 medications are no longer just “weight-loss drugs.” They are anti-inflammatory, metabolically active medications that, for the right patients, can meaningfully improve arthritis and autoimmune disease — not by replacing your DMARDs or biologics, but by making them work better and protecting your heart along the way. The strongest evidence right now is in knee osteoarthritis (the STEP-9 trial) and rheumatoid arthritis (the UCLA cohort), with rapidly growing data in psoriatic arthritis and lupus.

If you live with arthritis or an autoimmune condition and you’re curious whether a GLP-1 medication — or a microdose — might fit into your care, that’s a conversation worth having with a rheumatologist who understands both the metabolic and the immune sides of the picture. Our team at Rheumatologist OnCall is here to help you figure out whether it’s right for you.

References

1. Bliddal, H. et al. Once-weekly semaglutide in persons with obesity and knee osteoarthritis (STEP 9). New England Journal of Medicine 391, 1573–1583 (2024). https://doi.org/10.1056/NEJMoa2403664
2. Kellner, D. A. et al. Effect of glucagon-like peptide 1 receptor agonists on patients with rheumatoid arthritis. ACR Open Rheumatology (2025). https://doi.org/10.1002/acr2.70103
3. Tsibadze, N. et al. Mortality and major adverse cardiac events (MACE) with GLP-1 receptor agonists in psoriatic arthritis. Abstract #0849, ACR Convergence 2025, Chicago, IL (October 24–29, 2025).
4. Buonanno, S. et al. The potential role of GLP-1 receptor agonists in the management of psoriatic disease: a scoping review. Inflammation Research (2025). https://doi.org/10.1007/s00011-025-02140-2

Medical disclaimer: This article is for educational purposes and does not constitute medical advice. GLP-1 medications have specific contraindications and side effects. Do not start, stop, or modify any medication without consulting your physician.

Diana Girnita, MD, PhD, FACR is a double board-certified rheumatologist and the founder of Rheumatologist OnCall, a virtual rheumatology practice serving women across multiple states. She holds a PhD in immunology and has dedicated her career to helping patients who have been dismissed by the conventional system finally get answers.